Question 1

Where is the Fresenius SE & Co. KGaA stock traded?

Accepted Answer

The Fresenius SE & Co. KGaA stock trades under the ticker FRE.XETRA on the XETRA exchange. ISIN: DE0005785604.

Question 2

What does Fresenius SE & Co. KGaA do?

Accepted Answer

Fresenius SE & Co. KGaA is a company characterized by the following investment thesis:

Question 3

What are the key metrics for FRE.XETRA?

Accepted Answer

Key metrics for FRE.XETRA include valuation (P/E 17, P/S 1.1, P/B 1.3), profitability (profit margin 6.54%, ROE 8.29%), and growth (revenue —, earnings —). Market capitalization is 26.51B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has Fresenius SE & Co. KGaA's stock price performed?

Accepted Answer

Fresenius SE & Co. KGaA's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is FRE.XETRA valued?

Accepted Answer

FRE.XETRA has the following valuation metrics: P/E Ratio: 17, P/S Ratio: 1.1, P/B Ratio: 1.3. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does FRE.XETRA pay dividends?

Accepted Answer

Yes, FRE.XETRA pays dividends with a dividend yield of 2.2%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in FRE.XETRA?

Accepted Answer

Key risks for FRE.XETRA include: Fresenius SE & Co. KGaA operates a diversified healthcare portfolio spanning dialysis through Fresenius Medical Care, pharmaceuticals and intravenous therapies via Fresenius Kabi, hospital operations through Fresenius Helios, and healthcare services through Fresenius Vamed. The company competes across multiple segments against integrated hospital operators, large multinational medtech and pharmaceutical firms, and specialized dialysis providers. Material risks stem from execution of acquisitions and transformation initiatives, shifts in healthcare reimbursement and financing structures, intensifying competition in dialysis and generic/IV therapy markets, and operational exposures including supply chain resilience, manufacturing quality, and IT and cybersecurity infrastructure.Large M&A and integration programs carry genuine risk of execution failure, which could trigger impairment charges and disrupt operations.Changes in public and private payer reimbursement rates or regulatory pricing policies pose a material risk to revenue and margins across hospitals, dialysis providers, and generic manufacturers.Intense rivalry from Baxter, B. Braun, DaVita, established medtech players, and low-cost regional suppliers creates meaningful pressure on pricing and market share, particularly across dialysis and IV/generic product lines.Operational, quality, and IT/cybersecurity risks stem from supply-chain disruptions, product quality issues, or cyberattacks, each capable of disrupting services, triggering recalls or regulatory sanctions, and damaging reputation [1].Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of Fresenius SE & Co. KGaA?

Accepted Answer

Fresenius SE & Co. KGaA competes with several listed peers in its sector. Fresenius SE & Co. KGaA operates across healthcare with exposure to competitive pressure from global medical technology firms, renal-care device manufacturers, large hospital operators, and multinational pharmaceutical and infusion companies. The group faces overlapping risks: healthcare financing and reimbursement constraints, competitive and innovation dynamics in dialysis and infusion products, and operational, quality, and regulatory challenges that span its hospital, dialysis, and pharmaceutical infusion divisions.Baxter International Inc. (BAX.NYSE)DaVita Inc. (DVA.NYSE)Medtronic plc (MDT.NYSE)Abbott Laboratories (ABT.NYSE)HCA Healthcare, Inc. (HCA.NYSE)Cardinal Health, Inc. (CAH.NYSE)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does Fresenius SE & Co. KGaA report earnings?

Accepted Answer

Fresenius SE & Co. KGaA's next earnings report date is November 4, 2026.

	2025	2024	2023	2022	2021
Revenue	22.87B	21.83B	21.07B	21.33B	37.08B
Operating income (EBIT)	2.50B	1.84B	1.29B	2.00B	3.60B
Net income	1.26B	471.00M	-594.00M	1.37B	1.82B
Free cash flow	1.20B	1.52B	3.32B	2.28B	3.03B
Total assets	41.40B	43.55B	45.28B	76.42B	71.96B
Equity	19.10B	19.54B	19.00B	20.41B	19.00B
Net debt	10.35B	11.53B	13.27B	25.59B	24.55B

Fresenius SE & Co. KGaA Financials

Key financial figures

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more